ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: Journal of Thrombosis and Haemostasis
Author(s): J.S. Paikin, J. Hirsh, J.S. Ginsberg, J.I. Weitz, N.C. Chan, R.P. Whitlock, G. Pare, J.W. Eikelboom
The authors randomized 68 patients undergoing CABG to three treatment groups:   ASA 81 mg QD ASA 325 mg QD ASA 162 mg BID On the 4th day following CABG, the authors measured serum thromboxane B2 (TXB2) as an inverse surrogate for ASA effect.  The order of TXB2 levels were as follows:  162 mg BID << 81 mg BID ≈ 81 mg QD.  Thus, the optimal regimen, according to this small study, would be ASA 162 mg BID.
Source: Circulation Research
Author(s): Jonathan R. Kaltman, Kristin M. Burns, Gail D. Pearson
Three quarters of a century in caring for patients with congenital heart disease are summarized well in this brief viewpoint article, with the big data issue discussed.   
Source: BBC Tyne & Wear
Author(s): BBC News
According to BBC Tyne & Wear, a patient died after surgeons inserted a heart valve upside down causing irreversible damage to her heart. The procedure was performed at the Freeman Hospital in Newcastle upon Tyne. NHS Foundation Trust has admitted the error, and the family has begun legal action. 
Source: Annals of Thoracic Surgery
Author(s): Jeremie Reeb, Anne Olland, Julien Pottecher, Xavier Delabranche, Mickael Schaeffer, Stephane Renaud, Nicola Santelmo, Romain Kessler, Gilbert Massard, Pierre-Emmanuel Falcoz
The authors report the use of ECMO in 8 pts who suffered ARDS after pneumonectomy.  Predicted mortality was 80% prior to ECMO institution.  ECMO was weaned in 7 pts and overall hospital survival was 50%.  
Source: Annals of Thoracic Surgery
Author(s): Tyson A. Fricke, Anne Eva Bulstra, Benjamin R. Loyer, Robert G. Weintraub, Yves d'Udekem, Christian P. Brizard, Igor E. Konstantinov
31 pts who underwent arterial switch at a weight of 2.5 kg or less were evaluated for outcomes.  Surgery was performed at an average of 16 days of life.  Mortality was 2.8% for those weighing 2.0-2.5 kg, and was 50% for those under 2 kg.  At a mean follow-up of 13 years, 8% had required late reoperation.  There were no late deaths, and all pts were NYHA Class I at last follow-up.  
Source: Annals of Thoracic Surgery
Author(s): Daisuke Yoshioka, Hiroo Takayama, Paolo C. Colombo, Melana Yuzefpolskaya, Arthur R. Garan, Veli K. Topkara, Jiho Han, Paul Kurlansky, Yoshifumi Naka, Koji Takeda
Changes in end organ function were assessed in 59 pts having a continuous flow LVAD in place for more than 3 years.  Renal and hepatic function improved initially, but renal function deteriorated to preoperative levels during the follow-up period.
Source: Annals of Thoracic Surgery
Author(s): Kosaku Nishigawa, Toshihiro Fukui, Masataka Yamazaki, Shuichiro Takanashi
The authors describe a 10-year experience with extended arteriotomy for endarterectomy of a diffusely diseased LAD, using an internal mammary artery for reconstruction.  Perioperative mortality was 1.1% and postoperative MI occurred in 9%.  Survival at 5 years was 89% and freedom from acute cardiovascular events was 74%.
Source: New England Journal of Mendicine
Author(s): André Lamy, P.J. Devereaux, Dorairaj Prabhakaran, David P. Taggart, Shengshou Hu, Zbynek Straka, Leopoldo S. Piegas, Alvaro Avezum, Ahmet R. Akar, Fernando Lanas Zanetti, Anil R. Jain, Nicolas Noiseux, Chandrasekar Padmanabhan, Juan-Carlos Bahamondes, Richard J. Novick, Liang Tao, Pablo A. Olavegogeascoechea, Balram Airan, Toomas-Andres Sulling, Richard P. Whitlock, Yongning Ou, Peggy Gao, Shirley Pettit, and Salim Yusuf, for the CORONARY Investigators
This trial randomly assigned 4,752 patients from 19 countries to either on-pump or off-pump CABG with a mean follow-up of 4.8 years.  The authors report no difference in death, stroke, myocardial infarction, renal failure or repeat revascularization at 5 years between the two groups.
Source: The Royal College of Surgeons of Edinburgh
Author(s): Pala B. Rajesh
The webinar will be presented by one of the UK’s most senior general thoracic surgeons, Mr. Pala B. Rajesh, and will entail a one-hour interactive session on “everything you need to know” about the thymus. The session, aimed at trainees and surgeons alike, will be broadcast on March 6 at 2:00 p.m., Central Time (8:00 p.m., GMT), and will be repeated on March 7 at 2:30 a.m., Central Time (8:30 a.m., GMT). Visit https://www.rcsed.ac.uk/professional-support-development-resources/learning-resources/webinars to register.
Source: JACC Cardiovascular Interventions
Author(s): Alexander C. Egbe, Heidi M. Connolly, Patricia A. Pellikka, Hartzell V. Schaff, Richard Hanna, Joseph J. Maleszewski, Vuyisile T. Nkomo, Sorin V. Pislaru
In this manuscript, the authors describe their findings in an observational prospective study of 52 patients who had tentative diagnoses of bioprosthetic valve thrombosis (BPVT) of surgically implanted valves over a 3-year period. All patients underwent a trial of anticoagulation therapy with warfarin, and follow-up transthoracic or transesophageal echocardiography performed at least 4 weeks after the initiation of anticoagulation therapy. The authors found that an echocardiographic diagnostic score predicted the response to warfarin anticoagulation in BPVT with excellent accuracy, that warfarin significantly reduced prosthetic gradients in 83% of the patients; and that this diagnostic and therapeutic strategy was associated with minimal side effects and no mortality.

Pages